HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025
SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in MET-high lung cancer, representing a ...
Psychology Today5h
Why Are We Captivated by Bad News?
Humans are wired to focus on bad news, amplified by media and algorithms. Mindful consumption and balanced perspectives can ...
Understanding the differences between enterprise and client SSDs
Understanding the differences between enterprise and client SSDs — from NAND endurance to performance optimization — is ...
Europol: Almost all forms of organized crime have a digital connection
From fraud and ransomware to drug trafficking: according to Europol, the internet has become the main arena for serious crime ...
Gender Bias In AI: Addressing Technological Disparities
This article examines the origins of AI bias and its consequences across different sectors and proposes actionable solutions ...
HUTCHMED Reports 2024 Full Year Results and Provides Business Updates
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we”) ...
HUTCHMED (China) Limited: HUTCHMED Reports 2024 Full Year Results and Provides Business Updates
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED", the "Company" or "we") (HKEX: 13; Nasdaq/AIM: HCM) today reports its financial r ...